The protocol provides evidence-based best practice criteria so that hospitals and other health settings can introduce animals into the care environment.
By following it, the RCN says services will be able to ensure the safety of patients and health care staff as well as the animals and their owners, while allowing patients to reap the benefits that interaction with animals can bring.
Publication of the protocol was prompted by an RCN survey last year which found that although the majority of respondents thought animals were hugely beneficial to patients, most nurses said animals were not allowed in their workplace.
The survey found that nine out of 10 nurses believe animals can help improve the health of patients with depression and other mental health problems with 60% of respondents also acknowledging that animals can help speed patient recovery.
Amanda Cheesley, RCN Professional Lead for Long-term Conditions and End-of-Life Care, said: "Anyone who’s worked in this area can see the amazing impact animals have on the health of adults and children alike.
"However there are so many myths around the dangers of having animals in health care settings that most organisations are too concerned to try it out.
"This protocol will help to dispel these fears by supporting hospitals to include animals in the care they deliver in a safe and professional way.
"We hope that it will encourage all health services to consider how animals can help their patients and help us to remove the taboo from what is a really remarkable area of care."
The protocol has been welcomed by the British Veterinary Association. Simon Doherty, BVA Junior Vice President, said: "This new protocol highlights the importance of the bond between humans and animals. It also serves as a welcome reminder at the start of Mental Health Awareness Week of how caring for and interacting with ‘man’s best friend’ can help to relieve stress and enhance wellbeing and a sense of companionship.
"It’s positive that the working group consulted with a wide range of organisations on welfare and safety considerations in developing this protocol, as ensuring the wellbeing of both humans and animals in these settings is paramount. As a fellow member of the UK One Health Coordination Group, BVA is very pleased to see a joined-up and forward-thinking approach to this important area of work."
Photo: Therapy Dog Visiting Young Female Patient In Hospital, Monkey Business Images / Shutterstock
Achieved by VMG members who have demonstrated an ability to effectively manage a veterinary practice, hospital or unit, the CVPM is aimed at experienced managers and members of the veterinary team in a leadership or management role. The qualification tests the knowledge of candidates in areas including management, HR, communication, marketing and financial planning.
VMG Director Georgina Hills (pictured right) said: "Effective veterinary leaders require expertise in all aspects of running a successful business, as well as a deep understanding of the veterinary sector and the CVPM is unique in testing their knowledge across the board. It is increasingly recognised as a benchmark for excellence and we are delighted to have seen an uplift in applications last year."
Further details on the CVPM and the application form are available here: https://www.vetmg.com/education/cvpm/
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
The new code is one of a series of welfare codes currently being reviewed and updated by the Department for Environment, Food and Rural Affairs (Defra) following recent consultations.
BVA President John Fishwick said: "We warmly welcome these updates and we are particularly pleased to see the vital role the veterinary profession plays in maintaining poultry welfare recognised throughout the new code.
"We are also delighted to see the benefits of veterinary surveillance systems highlighted, with owners and keepers encouraged to use local and national disease surveillance sources to better understand poultry disease patterns and their local health and welfare landscape. This was a key element in our joint consultation response and reflects BVA’s recently published Position on veterinary scanning surveillance (animal health and disease monitoring).
"We are also pleased to see signposting within the Code of Practice to the Humane Slaughter Association’s Code of Practice for the Disposal of Chicks in Hatcheries, which outlines in detail information about humane methods of killing and good practice.
"The British poultry industry has some of the highest welfare standards in the world and the veterinary profession is fully committed to working with Defra on further enhancing animal welfare codes to reflect best industry practice."
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
Reference
Elanco Companion Animal Health has launched of Dexdomitor 0.1 mg/ml, adding to its range of alpha-2 agonists and antagonists.
Produced and manufactured in partnership with Orion Corporation, Elanco says Dexdomitor 0.1 mg/ml contains all the properties of dexmedetomidine in a formulation that allows accurate and convenient dosing for the smallest patients. It can be used as a sedative for non-invasive, mild to moderately painful procedures and examinations which require restraint, sedation and analgesia in dogs and cats. It can also be used for deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures and as a pre-medication in dogs and cats before induction and maintenance of general anaesthesia.
Dexdomitor 0.1 mg/ml has been designed to provide accurate dosing in very small dogs (up to 5kg) for sedation and pre-medication, small to mid-size dogs (up to 20kg) for pre-medication, and small cats (up to 3kg) for sedation and pre-medication.
Ed Whittle MRCVS, technical consultant at Elanco Companion Animal Health said: "With nearly a quarter of dogs weighing less than 6kg and nearly three-quarters weighing less than 23.1kg1, Dexdomitor 0.1mg/ml is ideal for small animals that require low concentration doses of dexmedetomidine for convenient and accurate dosing".
Elanco has has also produced a sedation and pre-medication dosing guide to educate veterinary professionals on the recommended doses for its range of alpha-2 agonists and alpha-2 antagonists.
For further information contact your Elanco Companion Animal Health key account manager or email elancoCAH.uk@elanco.com.
Carl's article: 'Are you using a safety checklist in your practice?', focuses on the benefits of introducing a safety checklist in practice to reduce patient morbidity, mortality and to improve communication between members of the veterinary team.
He explains how a checklist helps eliminate the need to memorise every single step of a protocol and self-limit any errors that may eventually lead to a fatal or near-fatal incident, and how it should contain a limited number of elements, allow quick completion and most importantly be relevant to the situation.
The article includes information on how to introduce a safety checklist, steps to consider and how to use one in practice.
It also contains links to downloadable tools including the Association of Veterinary Anaesthetists (AVA) safety checklist and implementation booklet and information on the association’s ‘Safer Anaesthesia Project’. An editable safety checklist will also be available to download from the ‘Anaesthesia1ST’ blog that practices can adapt to their own requirements.
Richard Beckwith, country manager of Jurox (UK) said: "Our hugely popular Anaesthesia1ST newsletter features state-of-the-art, practical and easy to read articles to help veterinary professionals deliver 1ST class anaesthesia to all patients. Our latest edition will challenge practices to consider safety checklists as an essential part of their pre-anaesthetic routine in order to reduce the risk of mistakes."
To sign up to the Anaesthesia1ST newsletter visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at info@jurox.co.uk.
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
In the past, all practices that offered Carefree Credit to clients had to complete the FCA authorisation process, something which involved completing a 48 page online application and a wait of 12 weeks for approval. Although Carefree Credit provides guidance with the process and around 700 practices have enrolled successfully, it was not the ideal solution for practices who wanted a quick solution.
From now on, those practices that are happy to offer interest-free credit for a maximum period of 12 months can do so without going through the FCA process.
Stewart Halperin MRCVS, the founder of Carefree Credit, said: "For those of you who have looked at a client finance option for your practice but have been put off by the thought of going through the FCA authorisation process, this will make things much easier."
For more information, visit www.carefreecredit.co.uk/
Petplan's Veterinary Awards are designed to celebrate the nation’s most outstanding vets, vet nurses, practices, practice managers and support staff who are nominated by their colleagues and clients for continually going that extra mile, keeping pets healthy and giving owners peace of mind.
The independent panel of judges said that Johanna's nomination stood out for her ability to create a balance between leading a practice which maintains incredibly high clinical standards along with a welcoming, caring ethos with patients at the heart of everything they do.
Johanna said: "I’m absolutely ecstatic! I wasn’t expecting to win at all, so this is a real surprise – I just want to say thank you to those who nominated and all my staff for supporting me every day. What a brilliant feeling!"
The other big winner on the night was 387 Veterinary Centre. Two members of staff, Nicky Smith RVN and Joanne Civil, won 'Veterinary Nurse of the Year' and 'Veterinary Practice Support Staff of the Year' respectively, and the practice also took the overall 'Veterinary Practice of the Year' award.
'Veterinary Practice Manager of the Year' went to Anne Corson of Pennard Vets in Tonbridge.
The gilets, which normally cost $170, have three heating zones: one around the neck, one across the back of the shoulders and one which heats the pockets, all powered by a small battery.
VetSurgeon Editor Arlo Guthrie (pictured right) said: "As some members will know, I have a sideline reviewing gadgets and consumer tech on YouTube. Having reviewed the Ororo gilet, I bought a number of them for myself and my family, but thanks to a mix up by Amazon, I ended up with a spare men's XL size gilet (45-48 inch chest, 40-43 inch waist and 46-49 inch hip) .
"I'd like it to go to a good home, and I thought maybe a veterinary surgeon or nurse who now has to attend to clients in a frosty car park might be very glad of it.
"Of course, there are more women than men in the profession, so I'm going to offer one of the womens' vests too."
To win one of the gilets, watch the review here: https://www.youtube.com/watch?v=l84lRgEN1s4, then email: support@vetsurgeon.org with the answer to the following question:
On the medium heat setting, how long does the Ororo heated gilet stay warm?
First two correct answers out of the hat from those received by close of play next Wednesday (13th January) will get the gilets.
Arlo added: "Good luck, and a very happy New Year to you all. Let's hope we all get the vaccine soon.
"Oh, and if you enjoy the review, do subscribe on YouTube!"
The company says that recent supply issues have been due to 'incredible' demand for Reconcile since it was launched in the UK in 2022, which greatly surpassed expectations.
Dr Lucy Chadwick, Head of Technical Services & Marketing at Forte Healthcare Ltd said: “We realise that the recent supply issues have been very inconvenient so we thank all of our customers for their patience and support during this challenging time.
"We are confident that our supply issues to date have been resolved and that we have enough stock going forward to meet market demand.“
www.reconcilefordogs.com
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
California-based Signostics, Inc. has launched SpeqViewTM, billed as the world's smallest and most cost-effective veterinary ultrasound device.
Using MotionScape and SectorView technology, and offering multiple transducer frequencies, the SpeqView delivers high-resolution images for key veterinary applications including: cystocentesis; bladder volume; foreign object localization; abdominal imaging; and musculo-skeletal diagnosis.
Jeff Green, Signostics Vice-President of Sales and Marketing said: "The SpeqView provides a break-through for veterinary practices. For the first time there is an ultrasound device that is highly portable, simple to use and individually affordable. The SpeqView improves veterinary practice efficiency and income by allowing immediate diagnosis in the consulting room, or in the field and by providing better animal care.
He added: "Weighing a little over half a pound, the SpeqView features extended battery life and amazing portability, and is worn around your neck like a stethoscope or placed in your pocket until the next use."
The SpeqView is configured to use 3.5MHz and 7.5MHz transducers and comes with a comprehensive warranty, which covers the system and transducers and eliminates the need for annual service contracts. Signostics also offers extensive training and education programs delivered on site, online and in collaboration with leading veterinary institutions and educators. No interest, twelve-month financing is available.
For more information visit www.SpeqView.com or contact Signostics on 001 877 5744667.
The RCVS Operational Board has announced that it will ask Council to review its decision to remove postgraduate postnominals from the Register, following the largely negative response from the profession to the idea, including a petition from Derbyshire surgeon, Victoria Lilley.
The original decision was made by Council in June 2012 as part of a package of measures aimed at developing clarity around postgraduate skills and knowledge.
The College says that the removal of postgraduate postnominals from the Register was intended to help dispel confusion amongst the public and some members of the profession about the level of various qualifications, by introducing the Advanced Practitioner status alongside the existing Specialist list.
Chairman of the Operational Board, CEO Nick Stace, said: "Over the last few days we have listened to the disquiet amongst the profession - which has included direct contact with staff and Operational Board members, a petition and discussion on fora and social media - and feel that we should address some misunderstandings but also give Council the opportunity to review the decision at its 5 June meeting.
"Many good points have been made by members of the profession and I am pleased that the Operational Board has agreed to reflect on them and consider whether there is a better way to achieve the clarity we were seeking for the public and the profession.
"The introduction of Advanced Practitioner status is a positive move for both the profession and the public, and underlines the College's commitment to lifelong learning.
"It is important to have the profession's support for the direction we are taking in advancing standards across the sector."
The College has also provided some Q&A's concerning the original decision made by Council in 2012, as follows.
Norbrook Laboratories Ltd has launched Cleanor, an ear cleaner for cats and dogs.
Norbrook says Cleanor Ear Cleaner has been developed for regular, routine cleaning to help remove excessive ear wax from the ear canal as well as providing a moisturising effect to the ear canal's delicate epithelium.
Michelle Jones, Norbrook Brand Manager (Small Animals) said: "Ear disease represents one of the most common skin problems seen in veterinary practice. Checking the cat or dog's ears should be part of the normal health routine for pet owners. Cleanor Ear Cleaner has been designed to make the ear cleaning process simple and stress free for both the animal and owner. It comes with a long, soft and flexible nozzle to allow easy access to the ear canal and is gentle enough to treat even the most sensitive ears."
Cleanor Ear Cleaner is available in two sizes: 50ml and 120ml. It is supported by educational brochures to assist veterinary practices in discussing good ear cleaning practice with their clients. The brochures are available through Norbrook's local sales representatives.
Cleanor Ear Cleanor is available in the UK, Northern Ireland and the Republic of Ireland.
The aim of the survey, which closes on 16th June, is to recognise and help raise awareness of the multiple challenges faced by veterinary surgeons undertaking roles for Government as a distinct subset of the veterinary profession.
The Association of Government Veterinarians says that following the survey, it'll be producing a report which identifies issues which affect government vets' wellbeing, identifies existing tools to promote wellbeing within Government and considers developing new ones if necessary. It will also consider best practice and any gaps in the wellbeing services currently available that vets in Government roles would benefit from.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/vetswellbeing
You can read more about the survey here: https://vets.blog.gov.uk/2018/04/06/how-are-you-feeling-association-of-government-vets-wellbeing-survey-launched/
Photo: Christine Middlemiss introduces the survey.
Krka says the new pack, available for cats and for toy, small, medium and large dogs, is designed to offer practices greater dispensing flexibility and to encourage quarterly visits and compliance with healthcare plans.
Selehold is presented in a pipette with a colour-coded cap and transparent tube to enable the owner to check when the full dose has been given. Each pipette is individually wrapped for ease of use and dispensing.
Ms Sabrina Jordan, Country Brand Manager for Krka, said: "We aim to optimise the value we give to our customers by offering them highly effective, tried and trusted, affordable generic medicines with added value.
"Selehold has proved a popular addition to our parasite control range because of its ease of use and cost-effectiveness.
"With many of our customers focusing on encouraging owners to visit the practice quarterly and to sign up to a healthcare plan for their pet, the 3-pack version of Selehold works well as it enables the practice to offer clients a high quality, good value solution that supports this compliance framework."
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
Norbrook has verified that the pH of certain batches has increased over time and is out of specification.
This issue impacts the following batches:
A spokesperson said: "There has been no increased risk to animal safety identified but we take quality extremely seriously so we initiated a voluntary recall. We have informed all of the competent authorities and we are working with our distributor to advise immediate quarantine of any remaining inventory."
If you have any questions concerning the recall, contact Ms. Anita Vanderlaan Tel: +44 (0)28 3026 4435, Email: anita.vanderlaan@norbrook.co.uk
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
The pair were invited to carry out the laparoscopic surgery on four dogs suffering from pulmonic stenosis by the British Veterinary Centre.
Chris Linney said: “The British Veterinary Clinic had previously referred a case to Fabio at Willows and subsequently got in touch about a further four cases in need of surgery, inviting us to fly out to Abu Dhabi to operate on these cases for them.
“It was a pioneering moment for the British Veterinary Centre and a first for the region and the Middle East.
“It’s the very first time that interventional cardiology has been performed in the UAE so, with the fantastic facilities and dedicated staff at the BVC, we have made history in the region!
“It was also the first time that Fabio and I had worked together and now we hope that this will be the first of many such collaborations.”
Fabio added: “With our collective expertise and knowledge, we know we can improve the lives of so many dogs that are living with conditions like pulmonic stenosis.
“Two of the dogs required balloon valvuloplasty and two required pulmonary stents inserted.
“All four dogs had great initial post-operative results and would be expected to lead happier, healthier lives as a result of these procedures.'
MSD has announced that the broad-spectrum clostridial disease vaccine for sheep and cattle, Bravoxin 10, is now available in a new 6 x 100ml farm vaccination pack. The pack contains enough vaccine for 600 sheep or 300 cattle boosters.
Buyers of the new farm pack will also get a free vaccine applicator worth £20. The new Bravoxin 10 applicator benefits from the sterimatic system, which protects and sterilises the vaccination needle with each injection. MSD says it can also be placed down between doses without risk of needle damage, self-injection or needing to remove the vaccine bottle.
Bravoxin 10 protects both cattle and sheep from clostridial diseases like blackleg and black disease, as well as other conditions caused by clostridial bacteria that usually kill the animal once infection has become established. The vaccine protects against disease caused by the 10 main clostridial bacteria; C. perfringens type A, C.perfringens type B, C.perfringens type C, C.perfringens type D, C.novyi type B, C.septicum, C.tetani, C.sordellii, C.haemolyticum and C.chauvoei.